Back to Search Start Over

Penpulimab: First Approval

Authors :
Sohita Dhillon
Source :
Drugs. 81:2159-2166
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

Penpulimab (安尼可®) is a humanised anti-programmed cell death 1 (PD-1) monoclonal antibody developed by Akeso Biopharma, in collaboration with Chia Tai Tianqing (a subsidiary of SinoBiopharm), for the treatment of various cancers, including Hodgkin's lymphoma, nasopharyngeal cancer, non-small cell lung cancer (NSCLC) and solid tumours. Penpulimab is an immunoglobulin G1 monoclonal antibody engineered to completely eliminate Fcγ receptor binding and Fc-mediated effector functions that can compromise anti-tumour activity. In August 2021, penpulimab received its first approval in China for the treatment of adult patients with relapsed or refractory classic Hodgkin's lymphoma who have undergone at least second-line chemotherapy. Penpulimab is under regulatory review for nasopharyngeal cancer and NSCLC in China. Clinical studies of penpulimab are underway for various cancers in China and Australia. This article summarizes the milestones in the development of penpulimab leading to this first approval for relapsed or refractory classic Hodgkin's lymphoma.

Details

ISSN :
11791950 and 00126667
Volume :
81
Database :
OpenAIRE
Journal :
Drugs
Accession number :
edsair.doi.dedup.....8a25dec6a2de08d91cdf8321408b0f38